Coming competition in myasthenia gravis

A comparison of therapies that have shown promise, or failed to do so, in myasthenia gravis suggests targeting production of autoantibodies may be a less fruitful approach than blocking the effects of the autoantibodies or their recycling pathways.

Patients with the rare autoimmune disease generalized myasthenia gravis saw the first targeted therapy for the disease approved two years ago. Now, biopharmas are testing several new therapeutic mechanisms, with three different molecules slated to read out Phase III data by next year...